BlackRock Investment Management’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-4,926
| Closed | -$15K | – | 4015 |
|
|
2016
Q3 | $15K | Hold |
4,926
| – | – | ﹤0.01% | 3459 |
|
|
2016
Q2 | $7K | Sell |
4,926
-86,418
| -95% | -$198K | ﹤0.01% | 3788 |
|
|
2016
Q1 | $338K | Buy |
91,344
+1,614
| +2% | +$10K | ﹤0.01% | 3041 |
|
|
2015
Q4 | $906K | Buy |
89,730
+399
| +0.4% | +$4.8K | ﹤0.01% | 2661 |
|
|
2015
Q3 | $1.22M | Sell |
89,331
-647
| -0.7% | -$11.5K | ﹤0.01% | 2459 |
|
|
2015
Q2 | $1.71M | Buy |
89,978
+8,444
| +10% | +$183K | ﹤0.01% | 2363 |
|
|
2015
Q1 | $2.13M | Buy |
81,534
+552
| +0.7% | +$14K | ﹤0.01% | 1971 |
|
|
2014
Q4 | $1.7M | Sell |
80,982
-265
| -0.3% | -$6.68K | ﹤0.01% | 2151 |
|
|
2014
Q3 | $2.71M | Buy |
81,247
+607
| +0.8% | +$18.8K | ﹤0.01% | 1776 |
|
|
2014
Q2 | $2.59M | Buy |
80,640
+1,031
| +1% | +$38.4K | ﹤0.01% | 1878 |
|
|
2014
Q1 | $3.68M | Buy |
79,609
+376
| +0.5% | +$22.1K | 0.01% | 1605 |
|
|
2013
Q4 | $5.62M | Sell |
79,233
-1,951
| -2% | -$149K | 0.01% | 1264 |
|
|
2013
Q3 | $6.96M | Buy |
81,184
+4,773
| +6% | +$405K | 0.01% | 1085 |
|
|
2013
Q2 | $4.84M | Buy |
+76,411
| New | +$4.06M | 0.01% | 1239 |
|
BlackRock Investment Management's AEGR Position: Q4 2016 in Review
BlackRock Investment Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 4,926 shares — an estimated $15K sold.
BlackRock Investment Management first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $6.96M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- BlackRock Investment Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- BlackRock Investment Management sold 4,926 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $15K.
- BlackRock Investment Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- BlackRock Investment Management's Aegerion Pharmaceuticals position peaked at $6.96M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.